跳至主要内容
临床试验/NCT01080742
NCT01080742已完成不适用

A Prospective Observational Study to Evaluate the Efficacy of Lodoz in a Population of Hypertensive Patients

Merck KGaA, Darmstadt, Germany1 个研究点 分布在 1 个国家目标入组 1,007 人开始时间: 2010年1月最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
1,007
试验地点
1
主要终点
Mean systolic blood pressure (SBP) reduction and mean diastolic blood pressure (DBP) reduction at month 3 and 6 from baseline

研究概览

简要总结

This is an observational, prospective, non-interventional, non-randomised, open label multicentric study planned to be conducted in 1000 subjects with mild to moderate primary hypertension in approximately 20 centres in Thailand. The purpose of this study is to examine the beneficial effects of combination of bisoprolol with hydrochlorothiazide available as Lodoz in treatment of Thai subjects with mild to moderate hypertension. The outcome of the study would also provide information on the optimal daily dosage schedule as well as adherence of Lodoz.

详细描述

Essential hypertension is a heterogenous multifactorial disease affecting large number of population. Monotherapy treatment in hypertension is often unable to achieve the desired blood pressure (BP) goals and subjects even remain at significant risk for developing cardiovascular disease. The use of combination therapy as first line treatment for hypertension provides a solution to the management problems related to hypertension. Among combination drugs, low dose combinations are useful tools in treating large segments of hypertensive subjects because of their several advantages, such as simplified dosage regimens, improve compliance and hypertensive control, decrease dose dependent side effects as well as reduce costs.

OBJECTIVES

Primary objective:

  • To evaluate the efficacy of Lodoz therapy when used in routine clinical practice in subjects with mild to moderate essential hypertension.

Secondary objective:

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Signed written informed consent
  • Subjects diagnosed with mild to moderate essential hypertension
  • Subjects foreseen for Lodoz treatment for hypertension
  • Age ≥ 18 years

排除标准

  • Subjects treated with Lodoz before study initiation
  • Subjects who are pregnant
  • Subjects with any known contraindications to Lodoz based on local label

结局指标

主要结局

Mean systolic blood pressure (SBP) reduction and mean diastolic blood pressure (DBP) reduction at month 3 and 6 from baseline

时间窗: Baseline and until 6 months of treatment

次要结局

  • Proportion of subjects having reached target BP level, regarding Thai Hypertension Society guideline(After 3 and 6 months of treatment)
  • Response rate for DBP (defined as ≥ 10 mm Hg or DBP < 90 mmHg)(After 3 and 6 months of treatment)
  • Response rate for SBP (defined as ≥ 10 mm Hg or SBP < 140 mmHg)(After 3 and 6 months of treatment)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验